These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22277398)

  • 21. Coexistence of myasthenia gravis and Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient: A case report.
    Jia R; Chen J; Ge R; Zheng Q; Chen F; Zhao Z
    Medicine (Baltimore); 2018 Jun; 97(23):e10976. PubMed ID: 29879051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B; Phillips LH; Juel VC
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis?
    Sanders DB; Cao L; Massey JM; Juel VC; Hobson-Webb L; Guptill JT
    Clin Neurophysiol; 2014 Jun; 125(6):1274-7. PubMed ID: 24332471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
    Tarr TB; Wipf P; Meriney SD
    Mol Neurobiol; 2015 Aug; 52(1):456-63. PubMed ID: 25195700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging diversity of neuromuscular junction disorders.
    Newsom-Davis J
    Acta Myol; 2007 Jul; 26(1):5-10. PubMed ID: 17915563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases.
    Lorenzoni PJ; Scola RH; Kay CS; Parolin SF; Werneck LC
    Arq Neuropsiquiatr; 2010 Dec; 68(6):849-54. PubMed ID: 21243240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
    Hülsbrink R; Hashemolhosseini S
    Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome.
    Chaudhry V; Watson DF; Bird SJ; Cornblath DR
    Muscle Nerve; 1991 Dec; 14(12):1227-30. PubMed ID: 1662773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Nicolle MW
    Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1978-2005. PubMed ID: 27922503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myasthenia gravis Lambert-Eaton overlap syndrome.
    Oh SJ
    Muscle Nerve; 2016 Jan; 53(1):20-6. PubMed ID: 26418033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer.
    Liu Y; Xi J; Zhou L; Wu H; Yue D; Zhu W; Lin J; Lu J; Zhao C; Qiao K
    J Clin Neurosci; 2019 Jul; 65():41-45. PubMed ID: 31072737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.
    Skeie GO; Apostolski S; Evoli A; Gilhus NE; Hart IK; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW
    Eur J Neurol; 2006 Jul; 13(7):691-9. PubMed ID: 16834699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines for treatment of autoimmune neuromuscular transmission disorders.
    Skeie GO; Apostolski S; Evoli A; Gilhus NE; Illa I; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW;
    Eur J Neurol; 2010 Jul; 17(7):893-902. PubMed ID: 20402760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
    Quartel A; Turbeville S; Lounsbury D
    Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
    Vincent A; Lang B; Newsom-Davis J
    Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Standard treatment for late-onset myasthenia gravis in Japan].
    Motomura M
    Rinsho Shinkeigaku; 2011 Aug; 51(8):576-82. PubMed ID: 21878723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.
    Flink MT; Atchison WD
    J Physiol; 2002 Sep; 543(Pt 2):567-76. PubMed ID: 12205190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.
    Wirtz PW; Nijnuis MG; Sotodeh M; Willems LN; Brahim JJ; Putter H; Wintzen AR; Verschuuren JJ;
    J Neurol; 2003 Jun; 250(6):698-701. PubMed ID: 12796832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.